JPML Centralizes Patent Litigation Involving Type 2 Diabetes Drug Ozempic



DOCUMENTS
  • Order


WASHINGTON, D.C. — The Judicial Panel on Multidistrict Litigation has granted a request by Novor Nordisk Inc. and Novo Nordisk A/S to centralize their cases accusing various pharmaceutical companies of violating the patent for type 2 diabetes and weight loss drug Ozempic by seeking approval to make and sell generic versions of the medication.

In an Aug. 5 order, the panel ruled that centralization before Judge Colm F. Connolly of the U.S. District Court for the District of Delaware “will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation.”

“These …






UPCOMING CONFERENCES




HarrisMartin's MDL Conference: The Current Mass Tort Landscape - Best Management Practices & Updates on Key Litigation

September 28, 2022 - St. Louis, MO
Four Seasons Hotel, St. Louis

MORE DETAILS



HarrisMartin’s Webinar Series: Acetaminophen ASD/ADHD Product Liability Litigation

October 21, 2022

MORE DETAILS